Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Human Blood Cell Disorders Tissue Bank

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2016 by Northwell Health
Information provided by (Responsible Party):
Nicholas Chiorazzi, Northwell Health Identifier:
First received: May 13, 2009
Last updated: April 13, 2016
Last verified: April 2016
The Human Blood Cell Disorder Tissue Bank will provide a convenient, comprehensive source of tissue containing populations of human blood cells from patients with various types of lymphoid, myeloid, and erythroid proliferative diseases as well as other associated conditions. The tissue bank will continue to be an invaluable asset for understanding of the biology of multiple blood cell disorders involving several cell types as well as the physiology of normal cellular counterparts affected in these disorders. Internal and external investigators will be able to utilize this tissue to test hypotheses relating to the immunologic, virologic, genetic, and molecular properties of these abnormal cells as well as normal cells from normal unaffected family members or normal aged matched subjects to provide better comparisons.

Human Blood Cell Disorders
Lymphoid, Myeloid and Erythroid Proliferative Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Human Blood Cell Disorders Tissue Bank

Further study details as provided by Northwell Health:

Primary Outcome Measures:
  • Accumulate tissue from patients with various blood disorders, including but not restricted to lymphoproliferative, myeloproliferative, and erythroproliferative conditions. [ Time Frame: Indefinite ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Develop a database of at least 10,000 subjects who have donated samples for research as well as DNA banking, and who are willing to be contacted again for consideration of additional studies in the future. [ Time Frame: Indefinite ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
cells, tissue, serum, saliva, etc

Estimated Enrollment: 10000
Study Start Date: April 2009
Estimated Study Completion Date: January 2019
Estimated Primary Completion Date: January 2019 (Final data collection date for primary outcome measure)
Human Blood Cell Disorders
Human Blood Cell Disorders Tissue Bank


Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Community sample

Inclusion Criteria:

  • Participants or participant's Legally Authorized Representatives (LAR) must be able to understand and render voluntary, written informed consent.
  • Patients must be able to contribute the required amount of blood and/or tissue without compromising their well-being or care.
  • Participants must be willing to be contacted again for consideration of additional studies in the future, such as a blood draw or another action (e.g., bone marrow aspiration and/or biopsy) that would be done as part of their standard of care.

Exclusion Criteria:

  • Patients who are known to be anemic, with hemoglobin <8.0g/dl.
  • Patients who are known to be infected with HIV.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00902447

Contact: Yasmine Kieso, MSCR

United States, New York
The Feinstein Institute for Medical Research Recruiting
Manhasset, New York, United States, 11030
Contact: Yasmine Kieso, MSCR   
Principal Investigator: Nicholas Chiorazzi, M.D.         
Sponsors and Collaborators
Northwell Health
Principal Investigator: Nicholas Chiorazzi, M.D. The Feinstein Institute for Medical Research
  More Information

Responsible Party: Nicholas Chiorazzi, Investigator, The Feinstein Institute for Medical Research, Northwell Health Identifier: NCT00902447     History of Changes
Other Study ID Numbers: 08-202 
Study First Received: May 13, 2009
Last Updated: April 13, 2016
Health Authority: United States: Federal Government

Keywords provided by Northwell Health:
Human Blood Cell Disorders
lymphoid, myeloid and erythroid proliferative disease

Additional relevant MeSH terms:
Pathologic Processes processed this record on October 21, 2016